Abstract: Provided are food products having structures, textures, and other properties similar to those of animal meat, and that comprise substantial amounts of cell wall material. Also provided are methods and processes for producing such food products.

Abstract: The present invention primarily relates to the use of Homoeriodictyol (HED) or a salt thereof or a mixture of HED and one or more salts thereof or a mixture of several salts thereof for reducing the gastric acid secretion-stimulating effect of N-Acetyl-4-aminophenol (Paracetamol).

Abstract: Compositions comprising polysaccharides and oligosaccharides are provided. Methods for the formation of the compositions, including the enzymatic production of the oligosaccharides, and the uses of the compositions in foodstuffs, cosmetics, and nutraceuticals are also provided.

Abstract: Methods of preparing a delivery system are described. Each method uses a first and second printing materials. The second printing material contains an active material such as a fragrance, flavor, malodor counteracting agent, and mixture thereof.

Abstract: The present invention generally relates to the early prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children. For example, the present invention relates to the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children through appropriate nutrition for women desiring to get pregnant and/or during pregnancy and/or lactation. Embodiments of the present invention relate to the Vitamin B6 for use in the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in the offspring, wherein the vitamin B6 is administered to women desiring to get pregnant and/or to the mother during pregnancy and/or lactation and to maternal food compositions that can be used for this purpose.

Abstract: This invention provides a method of colonic cleansing.

Abstract: A synergistic herbal stimulant composition comprises a mixture, in powdered or extract form, of two or more herbal stimulant ingredients and at least one catalytic herbal ingredient, which effects a synergy between the herbal stimulant ingredients. The herbal stimulant ingredients are preferably selected from the group consisting of Horny Goat Weed (Epimedium Sagittatum), Rhodiola Root (Rhodiola Rosea), Elueuthero Root (Eleutherococcus), Nettle Leaf (Urticaria Dioica), Ashwagandha Root (Withania Somnifera), Maca Root (Lepidium Meyenii), Moringa Root (Moringa Oleifera), and Cowitch (Macuna Pruriens). The catalytic herbal ingredient is preferably Moses-in-a-basket (Tradescantia Spathacea).

Abstract: The invention provides a smokeless tobacco product comprising a tobacco extract. In some embodiments, the smokeless tobacco product is translucent. The invention further provides methods for making and using the smokeless tobacco product. In certain embodiments, the smokeless tobacco product comprises isomalt, maltitol syrup, and a translucent tobacco extract prepared by ultrafiltration.

Abstract: The present disclosure relates to the use of lipophilic mercaptans for the treatment of pain sensitization. The lipophilic mercaptans disclosed can be used to decrease the formation of protein-aldehyde adducts within nociceptive nerves, thereby reducing sensitization to pain.

Abstract: Generating an optimised formulation for a foodstuff, comprises receiving at a processor physicochemical data pertaining to one or more plant extracts and operating the processor to calculate a time, Tmax, representing a time to reach a maximum concentration in plasma of at least one metabolite of the one or more plant extracts by applying the received physicochemical data to a mathematical model stored in memory. The processor is then operated to identify ones of the metabolites for which the calculated Tmax substantially corresponds with a target absorption time for the foodstuff; and to generate an optimised formulation for the foodstuff comprising the one or more plant extracts containing the identified metabolites. The physicochemical data include one or more of molecular mass (M), liphophilicity (log P) and Polar Surface Area (PSA).

Abstract: The present invention relates to an agrochemical combination of (i) linolenic acid, a linolenic acid derivative, a linolenic acid breakdown component, or an ester thereof; and (ii) inositol, an inositol derivative or an inositol breakdown component. The invention also relates to agrochemical compositions comprising the same and the use such a combination for improving plant physiology.

Abstract: Methods are disclosed for the enzymatic preparation of galactooligosaccharide (GOS) from lactose using two different microbial lactase enzymes to maximize the extent of transgalactosylation during the digestion of lactose. Methods are also disclosed for avoiding the turbidity of a solution comprising GOS and lactose as it is adjusted for incubation with a yeast neutral lactase.

Abstract: A pharmaceutical composition of the present invention is used for improving health, cure abnormalities and degenerative disease; achieve anti-aging effect of therapy and therapeutic effect on mammals. The pharmaceutical composition includes a pharmaceutical carrier and an isotope selective ingredient including at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100%. A method of the present invention uses the inventive pharmaceutical composition to improve health, cure abnormalities and degenerative disease and achieve therapeutic effect on mammals.

Abstract: This disclosure relates to a supplement, particularly a supplement for menopause.

Abstract: The present disclosure provides for methods and compositions for the treatment and prevention of antibiotic-resistant infections or pathogen colonization in critically ill patients in the intensive care unit (ICU) or in other populations at high risk for such infections.

Abstract: A method of increasing muscle mass and strength in mammals by orally administering a therapeutically effective amount of phosphatidic acid. The phosphatidic acid is preferably administered as a plurality of doses per day with at least one dose being administered during the anabolic window following exercise. Preferably, the method further includes the cotemporaneous administration of a therapeutically effective amount of creatine, optionally as phosphatidylcreatine. In addition or in the alternative, the method further includes the cotemporaneous administration of a therapeutically effective amount of leucine, optionally as phosphatidylleucine.

Abstract: A dietary supplement including monacolin K, phytosterols, policosanols, resveratrol, trimethylglycine and coenzyme Q10 is provided.

Abstract: Disclosed herein are triglyceride based formulations, compositions, and methods for the treatment of otic diseases and conditions. Such triglyceride based formulations and compositions are derived from medium chain triglycerides and allow for the delivery of a variety of therapeutic agents to the outer, middle, and/or inner ear.

Abstract: An encapsulated reactant(s) having at least one encapsulant and at least one reactant. An outermost encapsulant is substantially non-reacting, impermeable and non-dissolving with water. The reactant(s) contribute to at least one reaction with contaminants in environmental media rendering the environmental media less harmful. Processes for using the encapsulated reactant in environmental media is also hereby claimed.

Abstract: Embodiments of the present invention are directed to methods, apparatus and articles of manufacture that feature omega-3 fatty acids co-processed with flavonoid and lipophilic antioxidants for improved stability.

Abstract: Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.

Abstract: An iron-based composition is described. The composition can be used in conditions of total or relative iron deficiency. In particular, a solid composition is described, preferably in the form of powder or granules, for use in the treatment of disorders or diseases related to or derived from an iron deficiency. The composition is suitable for pediatric subjects, adolescents, athletes, men, women, pregnant women and elderly. Finally, a process for preparing the solid composition is also described.

Abstract: A weight loss composition including banaba leaf extract, apple fruit extract, Rhodiola root extract, zinc chelate, and magnesium chelate are described. The weight loss composition may further include gardenia fruit extract, chromium chelate, Salacia extract, berberine, inositol, or mixtures thereof. Embodiments are also directed to a bulk food product and a weight management plan, which may be used in conjunction with the weight loss composition. Embodiments are also directed to kits and methods of use for treating or preventing obesity, promoting weight loss, and improving insulin resistance.

Abstract: This document provides dietary supplement compositions as well as methods for using dietary supplement compositions to control glucose levels. For example, a dietary supplement composition including chromium (e.g., Chromium Oligofructose Complex), a sweet potato extract, and one or more of a mulberry extract, a green tea extract, a cinnamon extract, or a ginseng extract (e.g., Korean Red Ginseng extract) are provided.

Abstract: Method of reducing the mTOR pathway stimulating activity of amino acid containing nutritional materials. This method comprises treating an enzymatically hydrolysed protein material such as casein, whey, or soy protein with at least one enzyme capable of converting mTOR pathway stimulating amino acids and amino acid residues, such as leucine or methionine, into alternate chemical entities that do not stimulate or stimulate to a significantly lesser degree the mTOR pathway, while preserving the non-mTOR stimulating amino acids. These one or more alternate chemical entities should ideally be suitable for consumption, or alternatively be capable of being removed from the treated material through low cost extraction or conversion techniques. The material may then be sold as is, or alternatively packaged with low glycemic carbohydrates, healthy lipids, vitamins, and flavors and sold as a variety of different food products intended for an artificial diet intended to mimic the effects of caloric restriction.

Abstract: Filmogenic compositions are described for topical anaesthetic bioadhesives (TABs) comprising a) a xanthan biopolymer matrix selected from Xanthomonas species and pathovars, including Xanthomonas campestris pathovars campestris and maninhotis, and Xanthomonas arboricola pathovar pruni, a producer of pruni xanthan, wherein the matrix is made of pure or combined xanthan varieties in any proportion, said matrix comprising between 1% and 95% by weight of the total weight of the composition, and additives or excipients; b) at least one anaesthetic, in a proportion of 0.1% to 50% by weight of the total weight of the composition. The topical anaesthetic bioadhesives (TABs) are also described, and they may be applied to the gingival mucosa and/or alveolar mucosa on the buccal (1) or lingual/buccal (2) surfaces with extensions and anatomical contours for crowns of the upper and lower dental arches.

Abstract: The present disclosure discloses a nutritional composition for nourishing heart. The nutritional composition includes: 58-83 parts by weight of rice, 7-25 parts by weight of red beans, 5-16 parts by weight of lotus seeds, 2-7 parts by weight of lilium brownii, and 0.4-1.6 parts by weight of longan. The present disclosure, in view of the heart's characteristics that clearing away the heart fire and calming the nerves can ward off diseases and prolong life, and prevent premature aging, provides the prescription with the purpose of nourishing the blood and tranquillizing, is suitable to cooperate with staple foods for long-term consumption and easily accepted by people due to the good taste, and can achieve certain efficacies of nourishing the heart and tranquillizing.

Abstract: Carrageenan-based compositions containing a carrageenan, a starch, a plasticizer, water, and an optional buffer are disclosed, in which the carrageenan has both a potassium content of less than 4 wt. % and a viscosity configured to produce capsules on pressure-free rotary die equipment. Films and capsules can be formed from the carrageenan-based compositions.

Abstract: The present application discloses a nutritional composition for tonifying spleen. The nutritional composition includes the following components of raw materials in parts by weight: rice 50-90, soybean 8-23, Semen coicis 2-12, Gorgon euryale seed 3-12, poria 0.4-1.6, and Chinese date 0.3-1.5. The present disclosure, in view of the spleen's special susceptibility to dampness pathogen, complies with the physiological function characteristics of the spleen itself, provides the prescription with an assistant effect of restoring the spleen's function as a starting point, is suitable to cooperate with staple foods for long-term consumption and easily accepted by people due to the good taste, and can achieve certain efficacies of tonifying the spleen and removing dampness.

Abstract: Preparations of glycan therapeutics, pharmaceutical compositions and medical foods thereof, optionally comprising micronutrients, polyphenols, prebiotics, probiotics, or other agents are provided and methods of making same. Also provided are methods of using said glycan therapeutics, e.g. for the modulation of human gastrointestinal microbiota and to treat dysbioses.

Abstract: There is disclosed a composition for oral administration of O-desmethyltramadol. Compositions are also provided that are effective for overcoming resistance to tramadol in patients.

Abstract: The present application discloses a nutritional composition for moisturizing lung. The nutritional composition includes the following components of raw materials in parts by weight: rice 55-90, wheat 7-25, Chinese yam 3-15, lily 2-9, polygonatum odoratum 0.2-1, and citron 0.1-1. The present disclosure, in view of the lung's characteristics of being not resistant to cold or heat, and susceptible to pathogen, complies with the lung's physiological function characteristics to regulate, and provides the prescription with nourishing yin and moisturizing lung, and resolving phlegm and relieving cough as a starting point, is suitable to cooperate with staple foods for long-term consumption and easily accepted by people due to the good taste, and can achieve certain efficacies of replenishing and restoring lung qi.

Abstract: The invention provides liquid formulations of compounds that act at sulfonylurea receptors that are suitable for intravenous and intra-arterial infusion. Compounds active at a sulfonylurea receptor include glibenclamide, tolbutamide, repaglinide, nateglinide, meglitinide, midaglizole, LY397364, LY389382, glyclazide, and glimepiride. Liquid formulations may be concentrated solutions suitable for storage; may be diluted (e.g., dilution of 1:1 or 1:1.2) suitable for bolus injections, and may be further diluted (e.g., dilution of 1:10 or 1:20 or more) for intravenous and intra-arterial infusion over an extended period of time. For example, a liquid formulation may include at least about 0.05 mg/ml glibenclamide in a water-based solution including 40% polyethylene glycol 300, 10% Ethanol, 50% water, at about pH 9. The solution may include a buffer, and is suitable for storage in refrigerator or at room temperature. This solution may be diluted 1:1, or more (e.g., 1:20) without precipitation of the glibenclamide.

Abstract: The present invention provides a composition comprising HMB and Vitamin D. Methods of administering HMB and Vitamin D to an animal are also described. Vitamin D and HMB are administered to increase muscle mass, strength, and functionality. The combination of Vitamin D and HMB together has a synergistic effect, which results in a surprising and unexpected level of improvement in muscle mass, strength and functionality.

Abstract: An object is to provide an acid milk beverage, which shows no precipitation or aggregation and reduced whey separation, and which has a refreshing texture, even in cases where the acid milk beverage has a low solids-not-fat concentration. An acid milk beverage characterized by containing an acid milk beverage base and a pectin having an intrinsic viscosity of 5.9 to 8.5, a degree of esterification of 74 to 80, and a calcium reactivity of 230 or less is provided.

Abstract: Provided herein is a ready-to-eat (RTE) breakfast cereal with a unique texture. A RTE breakfast cereal provided herein can have a high slowly digestible starch content relative to commercially available RTE cereals. Also disclosed are methods of making a RTE breakfast cereal described herein.

Abstract: The present invention provides nutritional compositions that are employed as oral supplementation to the human diet. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer. The present invention is comprised of specific combinations of selected forms of unique sets of certain vitamins, minerals, protein, carbohydrates and phytochemicals.

Abstract: The present invention relates to the field of the manufacture of food compounds derived from processing plant species, more specifically the process taught here provides products resulting from a process for obtaining compounds derived from vegetable raw material. The present invention describes the recovery of lecithin from the micelle/soy molasses, a residue obtained during the soy carrier concentrate (SPC) process. In a first aspect of the invention it describes a process for extracting phospholipids in conjunction with extraction of soluble sugars during the industrial process of obtaining (SPC). In a second aspect, the present invention describes an industrial process for recovering/removing such micelle phospholipids/soy molasses, cleaning and use for the production of soy lecithin.

Abstract: There is provided a tobacco product or a non-tobacco snuff product, including a magnesium carbonate, for conferring pH stability to the product and preventing growth of bacteria and fungi therein. The magnesium carbonate may contain hydroxide, oxide, and crystal water. The amount of magnesium carbonate ranges from 0.01 and 30% by weight of the dry bulk material. The product may be combined with additional pH regulators. The magnesium carbonate significantly increase the pH-stability in snus and non-tobacco snuff at the normal pH-range used in these products. The final product, which may be oral snuff or snus, or any tobacco-free snuff product, may be in particulate form, or shaped in a variety of forms. The product may be an oral product. The product may be packaged in a box, can or canister. Use of a magnesium carbonate for producing the products is also described.

Abstract: The present invention is directed to a new process for supplementation of beverages with soluble and bio available iron in the form of ferric pyrophosphate. This process allows iron supplementation of beverages at low cost, without affecting either the original taste or the colour of the beverages. It is also directed to a concentrate ferric pyrophosphate-citrate solution and its use in the preparation of an iron enriched beverage. The invention also relates to a beverage obtainable by this process.

Abstract: The use of propolis or an extract of propolis as a food supplement for preventing and/or combating pathological conditions associated with diet-induced obesity, and in particular type II diabetes, and a specific a composition suitable for this use.

Abstract: A method for enhancing cognitive development in a pediatric subject involving administering to the subject a nutritional composition which includes up to 7 g/100 Kcal of a fat or lipid; up to 5 g/100 Kcal of a protein or protein equivalent source; 0.25 g/100 Kcal to 16 g/100 Kcal of buttermilk; 5 mg/100 Kcal to 90 mg/100 Kcal of a source of long chain polyunsaturated fatty acid; and 0.015 g/100 Kcal to 1.5 g/100 Kcal of a prebiotic.

Abstract: A dosage form with a first portion and a second portion. The first portion can be an immediate release portion and can comprise a pain reliever, which can be naproxen or naproxen sodium. The second portion can be an extended release portion and can comprise pseudoephedrine or a pharmaceutically acceptable salt thereof and/or dextromethorphan or a pharmaceutically acceptable salt thereof. The dosage form can optionally comprise a stabilizing agent. The dosage form can be adapted to maintain a therapeutically effective amount of pain reliever, pseudoephedrine, or a pharmaceutically acceptable salt thereof, and/or dextromethorphan, or a pharmaceutically acceptable salt thereof, for at least eight hours.

Abstract: A method of maintaining the liquidity of coconut oil (i.e. organic virgin) at room temperature (76° F.) and below, while reducing the coconut taste, and significantly increasing the fat burning/ketone producing property by combining coconut oil (i.e. organic virgin) with medium chain triglycerides (MCT) in predetermined specific ratios, that includes the step of heating the coconut oil to a prescribed temperature for approximately 24 hours (or until liquidity is achieved) and then mixing the liquefied coconut oil with a specified ratio of MCT oil. The resultant composition is a neutral tasting, fat burning/ketone producing oil that remains a liquid at room temperature 76° F. (and below) for use in cooking and foodstuffs such as a salad dressing. In an alternate embodiment, an additional amount of olive oil (i.e. organic extra-virgin) or an omega-3 based oil can be added to further reduce the coconut flavor and enhance the health benefits of the composition.

Abstract: The present invention relates to a process for treating formation damage in an underground formation, including damage in the form of an oil-based drill-in fluid filter cake. The process makes use of a treatment fluid that contains a cyclodextrin or a starch and an enzyme capable of generating a cyclodextrin from the starch.

Abstract: This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO2 or CO2 plus approximately 5% of a co-solvent. Stage 2 extracts the actual krill oils by using supercritical CO2 in combination with approximately 20% ethanol. The krill oil materials obtained are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti-inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.

Abstract: A fungal strain Beauveria species bearing accession number MTCC 5184 is disclosed. The process for the preparation of an enzyme mix including at least one enzyme selected from, but not limited to protease, carbohydrase, and lipase from the disclosed Beauveria species and uses of the enzyme mix in various areas also disclosed.

Abstract: The present invention provides methods of assessing suitability of a pharmaceutical composition for medical use. The pharmaceutical composition comprises nanoparticles comprising paclitaxel coated with albumin and a non-nanoparticle portion comprising albumin and paclitaxel.

Abstract: A DAF skimmings separation system 10 that processes SPN/DAF skimmings 11 received from a meat processing facility to separate water and SPN-content solids includes a heating chamber coupled to a processor chamber having one or more pressurized discharge nozzles that expels DAF skimmings onto a spatter plate to cause SPN animal components within the DAF skimmings to break into smaller pieces denaturing the molecular structure and allowing the entrapped moisture to be evaporated within a heated airstream in the processing chamber, for separating nutritionally valuable SPN while reducing moisture content. A method of processing DAF skimmings to yield dryer SPN with reduced moisture content is disclosed.

Abstract: The invention relates to a microencapsulated amino acid composition and methods of manufacturing this composition. Amino acids, such as branched-chain amino acids, have low water solubility, poor hydrophilicity, and poor stability. Amino acids are thus difficult to be digested and absorbed. Consequently amino acids can hardly meet human needs of consuming. This microencapsulated amino acid composition that can quickly disperse and dissolve in cold water, resulting clear solution. The method includes (1) adding coating agents, wetting agents, or other excipients to the amino acid mixture, (2) modifying the surface of microencapsulated particles to considerably accelerate the wetting speed. In this composition, the weight ratio of amino acids and excipients is from 100/0.1 to 100/10.0.